Evidence mapPaperPMID 36743527Full record

ReviewTherapeutic advances in medical oncology2023

Targeting lipid metabolism in metastatic prostate cancer.

Tahlia Scheinberg, Blossom Mak, Lisa Butler, Luke Selth, Lisa G Horvath

Open access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in medical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
8.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Translational cancer research · 2024
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Tahlia ScheinbergMedical Oncology, Chris O'Brien Lifehouse, Camperdown NSW, Australia.ORCID https://orcid.org/0000-0003-4539-6216
Blossom MakMedical Oncology, Chris O'Brien Lifehouse, Camperdown NSW, Australia.ORCID https://orcid.org/0000-0003-3068-2498
Lisa ButlerProstate Cancer Research Group, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia.
Luke SelthSouth Australian Immunogenomics Cancer Institute and Freemason's Centre for Male Health and Wellbeing, University of Adelaide, South Australia, Australia.
Lisa G HorvathMedical Oncology, Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia.
The University of Sydney · AUFlinders University · AUSouth Australian Health and Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite key advances in the treatment of prostate cancer (PCa), a proportion of men have

Indexed as

high-fat dietlipidsprostate cancertargeted therapy

Identifiers

PMID36743527
PMCPMC9893394
OpenAlexW4318714395

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.